Bausch Health Companies enters the week after one of its worst monthly stretches in recent memory, with the stock off nearly 13% in a month and the options market deeply skewed toward downside protection — yet the borrow market shows no urgency at all.
The clearest signal this week is the put/call ratio. Options traders are running heavily defensive, with the PCR at 1.87 — well above its 20-day average of 1.82 and the highest the ratio has been since late August. That's not a z-score extreme, but with the 52-week high at 2.50, the market is clearly leaning bearish. The stock closed at $5.67 on Tuesday, down 4.2% on the day and 11.8% on the week, leaving it roughly 35% below the analyst consensus target of $7.63. That gap is eye-catching, but the analyst record here matters: RBC's April target cut to $9.00 and Barclays' February trim to $7.00 represent the most recent formal moves on the name, both lowering targets even while holding ratings. The consensus remains a cautious hold across all six covering analysts — a wall of "wait and see" rather than conviction either way.
The borrow market tells a strikingly different story. Availability is extremely loose — 145 million shares are available to borrow against a short position of just 7.7 million shares, putting availability at over 1,800% of short interest. That's not a tight market; it's one of the most comfortable borrow setups in the stock's recent history. Short interest itself has eased 7.8% over the past week to roughly 2.1% of the free float, after running higher through August when it briefly touched 9 million shares. Cost to borrow has collapsed 38% over the week to 0.57%. Short sellers are not pressing this decline with new positions — the price action is driven by something else.
That something else likely has roots in the activist shareholder register. This stock carries one of the most charged ownership structures in the specialty pharma space, and the 13D register makes that explicit. Paulson & Co. holds a 19.1% stake — nearly doubled from 8.9% in prior filings — after filing a Schedule 13D/A in August 2025. Alex Meruelo filed a separate 13D in April 2025 with a 9.99% position. Icahn Partners, meanwhile, held 9.4% as of its last 13D/A filing in August 2025, though its current position is undisclosed and could have changed materially. As the standard caveat requires: these stakes are as-last-disclosed around the 5% threshold, and positions can fall below that level without a further filing. Still, the concentration of activist capital here is unusual — the top three non-index holders account for well over a third of outstanding shares, a structural feature that limits the float available for normal trading and compresses the short opportunity.
The earnings history adds a specific dimension worth noting. The last two quarterly prints each produced day-one moves north of 33%, with five-day follow-through of 26-39%. The next event is scheduled for October 29. Those prior reactions were dramatic, but they reflect the company's volatile restructuring arc rather than a stable earnings cadence. The ORTEX EV/EBITDA multiple sits at roughly 6x — low in absolute terms and consistent with a company carrying heavy debt and an unresolved Bausch + Lomb separation overhang. The short score of 33.7 is in the bottom third of the universe, down from 36.7 at the start of September, suggesting declining short-seller pressure rather than intensifying conviction.
The setup into October 29 is therefore less about whether the borrow market will squeeze and more about whether the activist concentration ultimately forces a structural resolution — a separation timeline, a debt restructuring, or a strategic alternative — before the next print arrives.
See the live data behind this article on ORTEX.
Open BHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
